The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
SUMO: From Bench to Bedside
Open accessAbstract
Sentrin/small ubiquitin-like modifier (SUMO) is protein modification pathway that regulates multiple biological processes, including cell division, DNA replication/repair, signal transduction, and cellular metabolism. In this review, we will focus on recent advances in the mechanisms of disease pathogenesis, such as cancer, diabetes, seizure, and heart failure, which have been linked to the SUMO pathway. SUMO is conjugated to lysine residues in target proteins through an isopeptide linkage catalyzed by SUMO-specific activating (E1), conjugating (E2), and ligating (E3) enzymes. In steady state, the quantity of SUMO-modified substrates is usually a small fraction of unmodified substrates due to the deconjugation activity of the family Sentrin/SUMO-specific proteases (SENPs). In contrast to the complexity of the ubiquitination/deubiquitination machinery, the biochemistry of SUMOylation and de-SUMOylation is relatively modest. Specificity of the SUMO pathway is achieved through redox regulation, acetylation, phosphorylation, or other posttranslational protein modification of the SUMOylation and de-SUMOylation enzymes. There are three major SUMOs. SUMO-1 usually modifies a substrate as a monomer; however, SUMO-2/3 can form poly-SUMO chains. The monomeric SUMO-1 or poly-SUMO chains can interact with other proteins through SUMO-interactive motif (SIM). Thus SUMO modification provides a platform to enhance protein-protein interaction. The consequence of SUMOylation includes changes in cellular localization, protein activity, or protein stability. Furthermore, SUMO may join force with ubiquitin to degrade proteins through SUMO-targeted ubiquitin ligases (STUbL). After 20 yr of research, SUMO has been shown to play critical roles in most, if not all, biological pathways. Thus the SUMO enzymes could be targets for drug development to treat human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–214 of 214
Ren, S., Angrand, P., & Rijli, F. M. (2002) · Developmental Dynamics · doi:10.1002/dvdy.10171 · Cited by 37
Inhibition of SENP1 induces radiosensitization in lung cancer cells
Wang, R., Zhi, X., ZHANG, Y., & Zhang, J. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1259 · Cited by 36
Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor
Preuss, K., Pfreundschuh, M. G., Fadle, N., Regitz, E., & Kubuschok, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76802 · Cited by 34
Burdelski, C. M., Menan, D., Tsourlakis, M. C., Kluth, M., Hube‐Magg, C., Melling, N., Minner, S. J. P., Koop, C., Graefen, M., Hans Heinzer, A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1555-8 · Cited by 32
Involvement of activated SUMO-2 conjugation in cardiomyopathy
Kim, E. Y., Zhang, Y., Ye, B., Segura, A. M., Beketaev, I., Xi, Y. T., Yu, W., Chang, J., Li, F., & Wang, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.03.013 · Cited by 32
Wang, L., Qiao, G.-H., Hu, H., Gao, Z., & Nan, F. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00315 · Cited by 30
Li, T., Huang, S., Dong, M., Gui, Y., & Wu, D. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.03.007 · Cited by 25
Hsieh, M. M., Callacondo, D., Rojas-Camayo, J., Quesada-Olarte, J., Wang, X., Uchida, N., Marić, I., Remaley, A. T., Lèon‐Velarde, F., Villafuerte, F. C., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.02.010 · Cited by 24
Liu, F., Li, L., Li, Y., Ma, X., Bian, X., Liu, X., Wang, G., & Zhang, D. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4537 · Cited by 16
How do reducing equivalents increase insulin secretion?
Attie, A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci84011 · Cited by 12
Song, G. G., Choi, S. J., Ji, J. D., & Lee, Y. H. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.07.341 · Cited by 12
Tomosyn Interacts with the SUMO E3 Ligase PIASγ
Geerts, C. J., Jacobsen, L., van de Bospoort, R., Verhage, M., & Groffen, A. J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091697 · Cited by 10
Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor
Preuss, K., Pfreundschuh, M. G., Weigert, M., Fadle, N., Regitz, E., & Kubuschok, B. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82091 · Cited by 9
Reversible regulation of ORC2 SUMOylation by PIAS4 and SENP2
Wang, R., Liu, F., Zhao, Y., Wu, D., Chen, L., Yeh, E. T. H., & Huang, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19594 · Cited by 6
Self-citation
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
The Role of Sumoylation in the Response to Hypoxia: An Overview
Filippopoulou, C., Simos, G., & Chachami, G. (2020) · Cells · doi:10.3390/cells9112359 · Cited by 56
The function of SUMOylation and its crucial roles in the development of neurological diseases
Chen, X., Zhang, Y., Wang, Q., Qin, Y., Yang, X., Xing, Z., Shen, Y., Wu, H., & Qi, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202002702r · Cited by 39
Acuña, M. L., García-Morin, A., Orozco-Sepúlveda, R., Ontiveros, C., Flores, A., Diaz, A. V., Gutiérrez-Zubiate, I., Patil, A. R., Alvarado, L. A., Roy, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29357-7 · Cited by 19
Improved Peptide Search for Identification of SUMO and Sequence-Based Modifiers, in MaxSBM
Lennartsson, C., Kyriakidou, P., Nielsen, M. L., Olsen, J. V., Cox, J., & Hendriks, I. A. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101589
Metadata
- Authors
- Chang, H.-M., & Yeh, E. T. H.
- Venue
- Physiological Reviews
- Publisher
- American Physiological Society
- Published
- 2020-10-01
- Volume
- 100
- Issue
- 4
- Pages
- 1599-1619
- ISSN
- 0031-9333 (ISSN-L)
- 1522-1210
- OpenAlex
- W3043639762
- Cited by
- 355
- References
- 214
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.